UNSPSC 51434002: Enalpril

This classification denotes an antihypertensive agent with the molecular formula C20H28N2O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9O25354EPJ, chemically known as (Z)-but-2-enedioicacid;(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid, which bears US NIH Compound Identifier 5388961. SMILES: CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O.C(=CC(=O)O)C(=O)O.

UNSPSC 51434002 Enalapril, a Commodity code, covers pharmaceutical supply contracts that state and local governments procure for emergency medical services, health benefit programs, and institutional healthcare delivery. State and local buyers under this code are acquiring branded and generic medications—both single-line items for immediate operational use and comprehensive multi-source pharmaceutical catalogs to serve employee health plans and public health systems across multiple jurisdictions. Issuing bodies span city purchasing departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities across participating states including Oregon). The work involves direct manufacturer supply relationships, wholesaler-mediated distribution channels, and vendor compliance with FDA manufacturing standards, drug supply chain security, and expiration-date warranties.

Recent activity is concentrated in the South and Upper Midwest. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a one-year term and estimated contract value of $40,000, award by April 8, 2026 deadline. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) in late March 2026 exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement but no near-term contract opportunity. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026 and a two-year contract term; pricing is weighted at 75 percent of evaluation criteria, and vendors must maintain compliance with cGMP, DSCSA, and FDA expiration standards of at least one year from manufacture with six-month minimum shelf life. Tampa's IFB includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount, not to exceed $10,000.